• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Neuronetics Inc.

    4/9/26 4:05:38 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care
    Get the next $STIM alert in real time by email
    DEFA14A 1 ny20063283x2_defa14a.htm DEFA14A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    (Rule 14a-101)
    INFORMATION REQUIRED IN PROXY STATEMENT
    SCHEDULE 14A INFORMATION
    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
    (Amendment No.  )
    Filed by the Registrant ☑
    ​ ​
    Filed by a Party other than the Registrant  ☐
    Check the appropriate box:
     ☐
    Preliminary Proxy Statement
     ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐
    Definitive Proxy Statement
     ☑
    Definitive Additional Materials
     ☐
    Soliciting Material Pursuant to § 240.14a-12
    Neuronetics, Inc.
    (Name of Registrant as Specified in its Charter)
     
    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
    Payment of Filing Fee (Check all boxes that apply)
    ☑
    No fee required
     ☐
    Fee paid previously with preliminary materials
     ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11





    Get the next $STIM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $STIM

    DatePrice TargetRatingAnalyst
    7/20/2026$5.00Buy
    BTIG Research
    8/13/2024Outperform → Mkt Perform
    William Blair
    10/14/2021$18.00 → $12.00Market Outperform
    JMP Securities
    10/13/2021Outperform → Mkt Perform
    William Blair
    10/13/2021Buy → Neutral
    BTIG
    More analyst ratings

    $STIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Chernett Jorey bought $62,300 worth of shares (35,000 units at $1.78), increasing direct ownership by 0.33% to 10,588,988 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    7/15/26 9:33:19 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Large owner Chernett Jorey bought $117,000 worth of shares (100,000 units at $1.17), increasing direct ownership by 0.96% to 10,553,988 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    5/20/26 12:39:34 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Large owner Chernett Jorey bought $636,500 worth of shares (475,000 units at $1.34), increasing direct ownership by 5% to 10,453,988 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    5/13/26 8:31:28 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes

    Nir Naor appointed Chief Financial Officer effective July 23, 2026, bringing more than 20 years of finance and life sciences experienceCory Anderson promoted to Executive Vice President and General Manager, Greenbrook effective July 1, 2026Andrew Macan to step down as Executive Vice President, Chief Legal Officer & Corporate Secretary, effective August 15, 2026 MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that Nir Naor will be appointed Chief Financial Officer e

    7/20/26 4:05:00 PM ET
    $STIM
    $AXGN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Neuronetics to Participate in a Panel Discussion at B. Riley Securities' Mind, Muscle & Vision Summit on July 16, 2026

    MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that management will participate at the B. Riley Securities' Mind, Muscle & Vision Summit, an invitation-only institutional investor event being held in-person at the InterContinental Boston.Neuronetics will participate in a panel discussion titled "Commercializing the Next Wave of Novel Neuropsychiatric Drugs," alongside Compass Pathways, scheduled for Thursday, July 16, 2026. Management will also be available for one

    7/6/26 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Appoints Robert Greene as Senior Vice President Sales

    MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that Robert Greene has been appointed as the company's Senior Vice President Sales, effective June 1, 2026. Rob brings extensive experience leading commercial strategy and sales organizations within healthcare and medical technology, including capital equipment and service. Inducement Grant under Nasdaq Listing Rule 5635(c)(4) In connection with his hiring on June 1, 2026, the Co

    6/2/26 4:30:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    SEC Filings

    View All

    Neuronetics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Neuronetics, Inc. (0001227636) (Filer)

    7/20/26 4:10:04 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Neuronetics Inc.

    8-K - Neuronetics, Inc. (0001227636) (Filer)

    6/23/26 4:38:38 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    SEC Form SD filed by Neuronetics Inc.

    SD - Neuronetics, Inc. (0001227636) (Filer)

    5/29/26 5:28:14 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research initiated coverage on Neuronetics with a new price target

    BTIG Research initiated coverage of Neuronetics with a rating of Buy and set a new price target of $5.00

    7/20/26 9:06:40 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics downgraded by William Blair

    William Blair downgraded Neuronetics from Outperform to Mkt Perform

    8/13/24 10:26:16 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    JMP Securities reiterated coverage on Neuronetics with a new price target

    JMP Securities reiterated coverage of Neuronetics with a rating of Market Outperform and set a new price target of $12.00 from $18.00 previously

    10/14/21 8:41:45 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $STIM
    Leadership Updates

    Live Leadership Updates

    View All

    Large owner Chernett Jorey bought $62,300 worth of shares (35,000 units at $1.78), increasing direct ownership by 0.33% to 10,588,988 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    7/15/26 9:33:19 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    New insider Anderson Cory claimed ownership of 416,812 shares (SEC Form 3)

    3 - Neuronetics, Inc. (0001227636) (Issuer)

    7/13/26 4:15:06 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Director Amin Avinash disposed of 42,500 shares, decreasing direct ownership by 59% to 30,000 units (SEC Form 4)

    4 - Neuronetics, Inc. (0001227636) (Issuer)

    6/17/26 4:57:02 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Appoints Nir Naor Chief Financial Officer; Announces Additional Management Changes

    Nir Naor appointed Chief Financial Officer effective July 23, 2026, bringing more than 20 years of finance and life sciences experienceCory Anderson promoted to Executive Vice President and General Manager, Greenbrook effective July 1, 2026Andrew Macan to step down as Executive Vice President, Chief Legal Officer & Corporate Secretary, effective August 15, 2026 MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that Nir Naor will be appointed Chief Financial Officer e

    7/20/26 4:05:00 PM ET
    $STIM
    $AXGN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Neuronetics Appoints Robert Greene as Senior Vice President Sales

    MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that Robert Greene has been appointed as the company's Senior Vice President Sales, effective June 1, 2026. Rob brings extensive experience leading commercial strategy and sales organizations within healthcare and medical technology, including capital equipment and service. Inducement Grant under Nasdaq Listing Rule 5635(c)(4) In connection with his hiring on June 1, 2026, the Co

    6/2/26 4:30:00 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer

    MALVERN, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced the appointment of Dan Reuvers as the Company's next President and Chief Executive Officer, effective March 23, 2026. Mr. Reuvers will also join the Board of Directors at that time. He succeeds Keith Sullivan, who will step down as the Company's President and Chief Executive Officer on March 23, 2026 and retire on March 31, 2026 after five and a half years of leadin

    3/17/26 7:45:00 AM ET
    $IART
    $STIM
    $TCMD
    Medical/Dental Instruments
    Health Care

    $STIM
    Financials

    Live finance-specific insights

    View All

    Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM) (the "Company"), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, today announced that it plans to release first quarter 2026 financial and operating results prior to market open on Tuesday, May 5, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/3pztkve5. To listen to the conf

    4/21/26 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call

    MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics"), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it plans to release fourth quarter 2025 financial and operating results prior to market open on Tuesday, March 17, 2026. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-serv

    3/3/26 8:30:00 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Neuronetics Announces Selected Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results

    All values provided represent preliminary unaudited results Fourth quarter 2025 revenue of $41.8 million, representing 86% year-over-year growth on an as reported basis and 23% year-over-year growth on an adjusted pro forma basisFull year 2025 revenue of $149.2 million, representing 99% year-over-year growth on an as reported basis and 15% year-over-year growth on an adjusted pro forma basisAchieved positive operating cash flow of $0.9 million in the fourth quarter 2025Ended 2025 with total cash of $34.1 million, inclusive of cash, cash equivalents and restricted cash MALVERN, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc., (NASDAQ:STIM) (the "Company" or "Neuronetics") a verti

    2/10/26 4:34:49 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    $STIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Neuronetics Inc.

    SC 13D - Neuronetics, Inc. (0001227636) (Subject)

    12/17/24 9:15:11 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 1:42:23 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

    SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

    11/14/24 11:17:47 AM ET
    $STIM
    Medical/Dental Instruments
    Health Care